ArticleEuropean medical journal. Rheumatology2017
New Drug Treatments for Osteoarthritis: What is on the Horizon?
Article in European medical journal. Rheumatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 35 citations in OpenAlex.
- Joint Dysfunctionality Alleviation along with Systemic Inflammation Reduction Following Arthrocen Treatment in Patients with Knee Osteoarthritis: A Randomized Double-Blind Placebo-Controlled Clinical Trial.Medicina (Kaunas, Lithuania) · 2022Trial
- Evaluation of the Effect of Commiphora wightii and Asthiposhak in Experimental Rat Model of Osteoarthritis.Cureus · 2025Article
- Sodium tanshinone IIA sulfonate alleviates osteoarthritis through targeting SIRT1.Chinese medicine · 2025Article
- Serum Sirt6 as a Potential Biomarker for Osteoarthritis and its Correlation with IL-6 Alterations.Indian journal of orthopaedics · 2024Article
- Progress in the treatment of Osteoarthritis with avocado-soybean unsaponifiable.Inflammopharmacology · 2024Review
- Potential therapeutic strategies for osteoarthritis via CRISPR/Cas9 mediated gene editing.Reviews in endocrine & metabolic disorders · 2024Review
- Article
- Inflammatory Treatment Used to Mimic Osteoarthritis and Patients' Synovial Fluid Have Divergent Molecular Impact on Chondrocytes In Vitro.International journal of molecular sciences · 2023Article
- Patient characteristics, pain treatment patterns, and incidence of total joint replacement in a US population with osteoarthritis.BMC musculoskeletal disorders · 2022Article
- Small molecules of herbal origin for osteoarthritis treatment: in vitro and in vivo evidence.Arthritis research & therapy · 2022Review
- Burden, Treatment Patterns and Unmet Needs of Osteoarthritis in Dubai: a Retrospective Analysis of the Dubai Real-World Claims Database.Rheumatology and therapy · 2022Article
- Article
- Elucidation of Potential Targets of San-Miao-San in the Treatment of Osteoarthritis Based on Network Pharmacology and Molecular Docking Analysis.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Article
- Current Models for Development of Disease-Modifying Osteoarthritis Drugs.Tissue engineering. Part C, Methods · 2021Review
- Article
- Clinical Outcomes of Tanezumab With Different Dosages for Patient With Osteoarthritis: Network Meta-Analysis.Frontiers in pharmacology · 2021Article
- Therapeutic Potential of Bioactive Compounds in Honey for Treating Osteoarthritis.Frontiers in pharmacology · 2021Review
- Experimental Therapeutics for the Treatment of Osteoarthritis.Journal of experimental pharmacology · 2021Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Osteoarthritis (OA) is the most common form of arthritis, yet has historically lagged far behind rheumatoid arthritis in terms of drug development. Despite the many challenges presented by clinical trials in OA, improvements in our understanding of disease pathogenesis and a move to treat pain, as well as underlying disease process, mean there are now many new pharmacological therapies currently in various stages of clinical trials. The medical need for these therapies and the evidence for recent tissue and molecular targets are reviewed. Current therapeutic examples in each area are discussed, including both novel therapeutics and existing agents which may be repurposed from other disease areas. Some challenges remain, but opportunities for improving symptoms and disease process in OA in the clinic with new pharmacological agents would appear to be on the close horizon.
Indexed as
Identifiers
30364878PMC6198938W2910259961What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.